James Kehoe : Yes. So the — I’m just looking for the sale and leaseback. I think it was around 170 pre-tax. I don’t have an after-tax number. But we don’t — on a cash tax basis, we don’t pay very much tax on this because we have capital allowances — capital losses against it. In the UK, what we did was a technical update basically to reflect only currencies. So if currencies change in the future, we would adjust that. We have — I would describe it as a large degree of confidence in the base forecast in the international business. I would suggest that given how December came in, which was better than we expected, that 15% growth. And as I said, 40% of the profit is in December. So this takes — massively derisks the international forecast.
So I don’t — you never want to say anything is in the bag, but I think international is probably the very safe number. And just to cycle back a little bit on — everybody, I think, has been very, very focused on the 5% script growth rate. 2.5 percentage points comes from the marketing programs on the store reopening and 2.5 comes from market growth plus adherence programs, plus all the rest. So there is the possibility that we overperform on some of the other programs that will compensate for some of the risks that you perceive. And then two is just to dimensionalize this and — sorry, the labor on, but the change in the direction of procurement is $350 million and the change — second half versus first half and the volume change is 200. So if you were looking in terms of what’s going to have the biggest impact second half versus first half, it’s reimbursement, cost of goods sold changes versus first quarter and then it’s volume on the pharmacy business.
And I’m not saying it’s not important, but we have a very, very good line of sight to the reimbursement and we have decent line of sight to the cost of goods sold, and we have programs in place for the script volumes. So I just wanted to kind of close on that, kind of stealing your last question.
Operator: And this ends our Q&A session. I will now turn the call back over to Ms. Roz Brewer for some final closing remarks.
Roz Brewer : First of all, thank you, everyone, for joining us this quarter. We’ll conclude our Q&A but I want to end briefly by just recapping the main points that you heard from us today and then touch again on some of your questions. First of all, we have had a solid start to the year. Our results are broadly in line with expectations and our underlying sales growth is over 3% despite the tough environment we’ve all been in. Secondly, our core business is resilient, the convenience and value that we’re offering customers continue to resonate as we cycle from the COVID surge. And it reminds us every day that our brand remains strong and our customers are very loyal to us. Thirdly, our healthcare growth engine is showing great progress.
We’ve closed and accelerated major acquisitions, and this segment is expected to exit fiscal ’23 with positive adjusted EBITDA so we’re investing to grow in a very difficult time frame, but we remain committed to our strategy. Fourthly, we’re optimizing our portfolio. So our shares in AmerisourceBergen were sold with tight discounts and near 52-week highs, and we continue to have significant access to capital. And lastly, we’re maintaining guidance for the fiscal year, while controlling cost, and investing to grow to deliver our long-term sustainable value for all of you on this call. So thanks again for your support, and we wish you all a very Happy New Year. Thank you.
Operator: This concludes today’s conference call. Thank you for your participation. You may now disconnect.
